Patents by Inventor Richard T. Marconi
Richard T. Marconi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230355734Abstract: Provided herein are recombinant Factor H Binding Protein B (FhbB) chimeric proteins comprising several different mutant variants of the Treponema denticola Factor H binding protein B (FhbB). The mutant variants cannot bind Factor H. The chimeric proteins are used to vaccinate subjects against periodontal disease either systemically and/or by direct application of antibodies generated against the chimeric proteins to the oral cavity (e.g. the gums) of a patient to prevent and/or treat periodontal disease.Type: ApplicationFiled: October 5, 2021Publication date: November 9, 2023Inventor: Richard T. MARCONI
-
Publication number: 20220152180Abstract: Provided herein are chimeric recombinant polypeptides (chimeritopes) for use in vaccines against Anaplasmosis, in assays for diagnosing Anaplasmosis and in assays for measuring antibody titers induced by vaccination. The chimeritopes comprise, for example, antigenic segments of three Anaplasma proteins (OmpA, AipA and Asp14) and a non-antigenic segment of a Borrelia Osp protein (e.g. OspC) that is 10 amino acids in length, proline rich and random coil in conformation. Compositions comprising the chimeritopes, optionally in combination with additional Anaplasma proteins of interest, are also provided, as are methods of using the compositions as vaccines and diagnostic tools.Type: ApplicationFiled: February 1, 2022Publication date: May 19, 2022Inventors: Richard T. MARCONI, Jason A. CARLYON
-
Patent number: 11273213Abstract: Provided herein are chimeric recombinant polypeptides (chimeritopes) for use in vaccines against Anaplasmosis, in assays for diagnosing Anaplasmosis and in assays for measuring antibody titers induced by vaccination. The chimeritopes comprise, for example, antigenic segments of three Anaplasma proteins (OmpA, AipA and Asp14) and a non-antigenic segment of a Borrelia Osp protein (e.g. OspC) that is 10 amino acids in length, proline rich and random coil in conformation. Compositions comprising the chimeritopes, optionally in combination with additional Anaplasma proteins of interest, are also provided, as are methods of using the compositions as vaccines and diagnostic tools.Type: GrantFiled: April 17, 2019Date of Patent: March 15, 2022Assignee: Virginia Commonwealth UniversityInventors: Richard T. Marconi, Jason A. Carlyon
-
Publication number: 20210170006Abstract: Provided herein are chimeric recombinant polypeptides (chimeritopes) for use in vaccines against Anaplasmosis, in assays for diagnosing Anaplasmosis and in assays for measuring antibody titers induced by vaccination. The chimeritopes comprise, for example, antigenic segments of three Anaplasma proteins (OmpA, AipA and Asp14) and a non-antigenic segment of a Borrelia Osp protein (e.g. OspC) that is 10 amino acids in length, proline rich and random coil in conformation. Compositions comprising the chimeritopes, optionally in combination with additional Anaplasma proteins of interest, are also provided, as are methods of using the compositions as vaccines and diagnostic tools.Type: ApplicationFiled: April 17, 2019Publication date: June 10, 2021Inventors: Richard T. MARCONI, Jason A. CARLYON
-
Patent number: 10466240Abstract: Chimeric polyvalent recombinant proteins for use as vaccines and diagnostics for Lyme disease (e.g. in canines and humans) are provided. The chimeric proteins comprise epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types and/or OspE types. The OspC types may be associated with mammalian Borrelia infections.Type: GrantFiled: May 11, 2018Date of Patent: November 5, 2019Assignee: Virginia Commonwealth UniversityInventors: Richard T. Marconi, Christopher Earnhart, Lee D. Oliver
-
Patent number: 10266571Abstract: Antigenic polypeptides comprising linear immunodominant epitopes of Borrelia outer surface protein A (OspA) or Borrelia outer surface protein C (OspC) are useful as vaccines against Lyme disease, and as diagnostics for detecting Borrelia infections. The OspA and OspC antigenic polypeptides typically comprise a plurality of peptides representing epitope containing regions from multiple distinct phyletic groups. The antigenic polypeptides may also include epitopes from both Borrelia OspA and Borrelia OspC.Type: GrantFiled: November 25, 2016Date of Patent: April 23, 2019Assignee: VIRGINIA COMMONWEALTH UNIVERSITYInventors: Christopher G. Earnhart, Richard T. Marconi
-
Patent number: 10086057Abstract: Stage-specific Borrelia antigens for diagnosing, treating and/or preventing Lyme disease are provided. The antigens include chimeric Borrelia antigen constructs and mutant recombinant proteins comprising OspC and OspE epitopes, respectively. The antigens are used in multiprotein assays that differentiate early, middle and late stage infection, and/or in vaccine preparations.Type: GrantFiled: October 8, 2015Date of Patent: October 2, 2018Assignee: Virginia Commonwealth UniversityInventors: Richard T. Marconi, Lee D. Oliver
-
Publication number: 20180275126Abstract: Chimeric polyvalent recombinant proteins for use as vaccines and diagnostics for Lyme disease (e.g. in canines and humans) are provided. The chimeric proteins comprise epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types and/or OspE types. The OspC types may be associated with mammalian Borrelia infections.Type: ApplicationFiled: May 11, 2018Publication date: September 27, 2018Inventors: Richard T. MARCONI, Christopher EARNHART, Lee D. OLIVER
-
Publication number: 20170252422Abstract: Stage-specific Borrelia antigens for diagnosing, treating and/or preventing Lyme disease are provided. The antigens include chimeric Borrelia antigen constructs and mutant recombinant proteins comprising OspC and OspE epitopes, respectively. The antigens are used in multiprotein assays that differentiate early, middle and late stage infection, and/or in vaccine preparations.Type: ApplicationFiled: October 8, 2015Publication date: September 7, 2017Inventors: Richard T. Marconi, Lee D. Oliver
-
Publication number: 20170114106Abstract: Antigenic polypeptides comprising linear immunodominant epitopes of Borrelia outer surface protein A (OspA) or Borrelia outer surface protein C (OspC) are useful as vaccines against Lyme disease, and as diagnostics for detecting Borrelia infections. The OspA and OspC antigenic polypeptides typically comprise a plurality of peptides representing epitope containing regions from multiple distinct phyletic groups. The antigenic polypeptides may also include epitopes from both Borrelia OspA and Borrelia OspC.Type: ApplicationFiled: November 25, 2016Publication date: April 27, 2017Applicant: Virginia Commonwealth UniversityInventors: Christopher G. Earnhart, Richard T. Marconi
-
Patent number: 9556239Abstract: A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammaliran Borrelia infections.Type: GrantFiled: August 1, 2014Date of Patent: January 31, 2017Assignee: Virgina Commonwealth UniversityInventors: Richard T. Marconi, Christopher Earnhart
-
Patent number: 9534021Abstract: Antigenic polypeptides comprising linear immunodominant epitopes of Borrelia outer surface protein A (OspA) or Borrelia outer surface protein C (OspC) are useful as vaccines against Lyme disease, and as diagnostics for detecting Borrelia infections. The OspA and OspC antigenic polypeptides typically comprise a plurality of peptides representing epitope containing regions from multiple distinct phyletic groups. The antigenic polypeptides may also include epitopes from both Borrelia OspA and Borrelia OspC.Type: GrantFiled: April 2, 2014Date of Patent: January 3, 2017Assignee: Virginia Commonwealth UniversityInventors: Christopher G. Earnhart, Richard T. Marconi
-
Patent number: 9376472Abstract: A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian Borrelia infections.Type: GrantFiled: June 9, 2014Date of Patent: June 28, 2016Assignee: Virginia Commonwealth UniversityInventors: Richard T. Marconi, Christopher Earnhart
-
Publication number: 20160097768Abstract: Chimeric polyvalent recombinant proteins for use as vaccines and diagnostics for Lyme disease (e.g. in canines and humans) are provided. The chimeric proteins comprise epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types and/or OspE types. The OspC types may be associated with mammalian Borrelia infections.Type: ApplicationFiled: October 8, 2015Publication date: April 7, 2016Inventors: Richard T. MARCONI, Christopher EARNHART, Lee D. OLIVER
-
Publication number: 20150064208Abstract: A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammaliran Borrelia infections.Type: ApplicationFiled: August 1, 2014Publication date: March 5, 2015Applicant: VIRGINIA COMMONWEALTH UNIVERSITYInventors: Richard T. MARCONI, Christopher EARNHART
-
Publication number: 20150044249Abstract: A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian Borrelia infections.Type: ApplicationFiled: June 9, 2014Publication date: February 12, 2015Inventors: Richard T. MARCONI, Christopher EARNHART
-
Patent number: 8808705Abstract: A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian Borrelia infections.Type: GrantFiled: October 19, 2011Date of Patent: August 19, 2014Assignee: Virginia Commonwealth UniversityInventors: Richard T. Marconi, Christopher Earnhart
-
Publication number: 20140212451Abstract: Antigenic polypeptides comprising linear immunodominant epitopes of Borrelia outer surface protein A (OspA) or Borrelia outer surface protein C (OspC) are useful as vaccines against Lyme disease, and as diagnostics for detecting Borrelia infections. The OspA and OspC antigenic polypeptides typically comprise a plurality of peptides representing epitope containing regions from multiple distinct phyletic groups. The antigenic polypeptides may also include epitopes from both Borrelia OspA and Borrelia OspC.Type: ApplicationFiled: April 2, 2014Publication date: July 31, 2014Applicant: VIRGINIA COMMONWEALTH UNIVERSITYInventors: Christopher G. Earnhart, Richard T. Marconi
-
Publication number: 20130266606Abstract: A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian Borrelia infections.Type: ApplicationFiled: October 19, 2011Publication date: October 10, 2013Applicant: VIRGINIA COMMONWEALTH UNIVERSITYInventors: Richard T. Marconi, Christopher Earnhart
-
Publication number: 20110262475Abstract: Antigenic polypeptides comprising linear immunodominant epitopes of Borrelia outer surface protein A (OspA) or Borrelia outer surface protein C (OspC) are useful as vaccines against Lyme disease, and as diagnostics for detecting Borrelia infections. The OspA and OspC antigenic polypeptides typically comprise a plurality of peptides representing epitope containing regions from multiple distinct phyletic groups. The antigenic polypeptides may also include epitopes from both Borrelia OspA and Borrelia OspC.Type: ApplicationFiled: May 1, 2009Publication date: October 27, 2011Inventors: Christopher G. Earnhart, Richard T. Marconi